Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3 registrational trial of pelareorep in HR+/HER2- metastatic breast cancer

Next Previous
Search
Trial Profile

A phase 3 registrational trial of pelareorep in HR+/HER2- metastatic breast cancer

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pelareorep (Primary)
  • Indications Advanced breast cancer; HER2 negative breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use

    • Most Recent Events

    • 27 Jun 2024 According to an Oncolytics Biotech media release, this study will enroll patients who have failed hormonal therapy and have received no more than one line of antibody-drug conjugate (ADC) therapy.
    • 27 Jun 2024 According to an Oncolytics Biotech media release, the Company has received productive feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), supporting this potential registration-enabling trial. The FDA supports progression-free survival as the primary endpoint of the study, and overall survival as a key secondary endpoint.
    • 12 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top